Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based ...

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Explore the LON:OXB financials. Find the Oxford BioMedica financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key ...

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you ...

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you ...

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved ...

Investing.com -- Oxford BioMedica shares fell 1.3% to 486.5 pence on Tuesday as investors digested a more cautious analyst view of ...

OXB reported continued commercial momentum in H1 2026 with half‑year revenue of GBP 80.2m (≈ +10% CC vs prior year), manufacturing up ~20%, and a growing, more diversified client base (59–60 active ...